🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 20 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
30/04/2019 38,28 38,83 37,01 37,42 -2,48% 4,75% 459.500
29/04/2019 39,27 39,54 38,18 38,37 -2,27% 3,46% 504.200
26/04/2019 38,65 39,64 38,22 39,26 +1,21% 3,67% 517.800
25/04/2019 37,15 38,90 36,95 38,79 +4,30% 5,25% 397.600
24/04/2019 36,61 37,44 35,90 37,19 +1,58% 4,22% 770.600
23/04/2019 36,47 36,90 35,80 36,61 +0,88% 3,02% 944.800
22/04/2019 35,80 37,95 35,80 36,29 +0,55% 6,01% 752.100
18/04/2019 35,45 36,28 34,51 36,09 +1,89% 4,99% 558.300
17/04/2019 37,91 38,07 35,29 35,42 -6,44% 7,33% 951.200
16/04/2019 38,67 38,67 37,58 37,86 -1,28% 2,82% 443.800
15/04/2019 37,46 38,41 37,05 38,35 +2,46% 3,63% 571.800
12/04/2019 38,79 38,94 37,15 37,43 -3,03% 4,61% 446.700
11/04/2019 39,47 40,32 38,01 38,60 -0,16% 5,85% 800.500
10/04/2019 37,90 39,21 37,87 38,66 +2,55% 3,52% 343.000
09/04/2019 36,87 38,30 36,58 37,70 +2,22% 4,67% 830.100
08/04/2019 38,02 38,03 36,82 36,88 -3,33% 3,17% 492.900
05/04/2019 37,64 38,30 37,31 38,15 +1,76% 2,63% 405.100
04/04/2019 38,02 38,02 36,78 37,49 -1,45% 3,26% 542.400
03/04/2019 38,58 38,69 37,42 38,04 -0,65% 3,29% 554.300
02/04/2019 37,99 38,82 37,75 38,29 +0,63% 2,82% 357.000
01/04/2019 37,95 38,24 37,31 38,05 +1,09% 2,45% 478.500
29/03/2019 36,87 37,96 36,47 37,64 +2,90% 4,04% 481.700
28/03/2019 36,28 37,14 35,67 36,58 +0,83% 4,05% 326.900
27/03/2019 36,89 37,05 35,55 36,28 -1,68% 4,07% 579.200
26/03/2019 37,80 37,91 36,42 36,90 -1,68% 3,94% 512.200
25/03/2019 37,75 38,20 37,03 37,53 -0,48% 3,10% 456.900
22/03/2019 39,13 39,67 37,64 37,71 -4,51% 5,19% 612.300
21/03/2019 37,35 39,63 37,20 39,49 +4,55% 6,51% 714.500
20/03/2019 37,51 38,18 36,82 37,77 +0,96% 3,63% 616.100
19/03/2019 36,97 37,48 36,21 37,41 +1,27% 3,44% 608.600